Cover Image
市場調查報告書

甲狀腺癌症的開發中產品分析

Thyroid Cancer - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 213074
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺癌症的開發中產品分析 Thyroid Cancer - Pipeline Review, H2 2014
出版日期: 2014年11月30日 內容資訊: 英文 110 Pages
簡介

甲狀腺癌是指甲狀腺內部異常細胞開始發達的疾病。甲狀腺位於頸部前方,呈蝶一般的形狀。此外更是生成荷爾蒙來消耗人體能量,及用於清潔體內。治療甲狀腺癌為外科手術、偶而使用放射性碘,幾乎不需要使用放射治療和抗癌劑治療。由於患者年齡和甲狀腺癌種類及階段(癌症發展狀況及擴散狀況)所用的治療法也有所變化。

本報告提供全球各國治療甲狀腺癌症用的開發中產品開發情形相關分析,彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)進展狀況),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

甲狀腺癌症概要

治療藥的開發

  • 甲狀腺癌症開發中產品:概要
  • 甲狀腺癌症開發中產品:比較分析

各企業正開發中的甲狀腺癌症治療藥

大學/研究機關研究中的甲狀腺癌症治療藥

開發中產品概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

甲狀腺癌症治療藥:開發中產品一覽(各企業)

甲狀腺癌症治療藥:研究中產品一覽(大學/研究機關別)

甲狀腺癌症治療藥的開發企業

  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • 武田藥品工業
  • Bio-Path Holdings, Inc.
  • Eisai
  • Bayer AG
  • Bionomics Limited
  • Azaya Therapeutics Incorporated
  • Vascular Biogenics Ltd.
  • Biovista Inc.
  • Trophogen, Inc.
  • centrose llc
  • Ecrins Therapeutics SAS

甲狀腺癌症:治療藥的評估

  • 單劑治療藥的情況
  • 併用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子種類別
  • 各治療分類

藥物簡介

  • sorafenib tosylate
  • lenvatinib
  • motesanib diphosphate
  • selumetinib sulfate
  • VB-111
  • dabrafenib + trametinib
  • dabrafenib
  • pazopanib hydrochloride
  • docetaxel liposomal
  • GSK-2256098
  • p53基因治療藥
  • BP-100-1.02
  • TRX-201
  • ETD-5
  • 血管內皮層成長因素的超強激動劑
  • 甲狀腺刺激素類似體
  • 藥物適合計劃
  • EDC-1
  • BVA-501
  • BVA-701
  • 肺癌症·甲狀腺癌症醫藥品
  • 甲狀腺癌症醫藥品

甲狀腺癌症治療藥:最新的藥物簡介

甲狀腺癌症治療藥:暫停開發的產品

甲狀腺癌症治療藥:中止開發的產品

甲狀腺癌症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5800IDB

Summary

Global Markets Direct's, 'Thyroid Cancer - Pipeline Review, H2 2014', provides an overview of the Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thyroid Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Thyroid Cancer - Overview
    • Pipeline Products for Thyroid Cancer - Comparative Analysis
  • Thyroid Cancer - Therapeutics under Development by Companies
  • Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  • Thyroid Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thyroid Cancer - Products under Development by Companies
  • Thyroid Cancer - Products under Investigation by Universities/Institutes
  • Thyroid Cancer - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Azaya Therapeutics Incorporated
    • Bio-Path Holdings, Inc.
    • Biovista Inc.
    • centrose llc
    • Ecrins Therapeutics SAS
    • Eisai Co., Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Translational Therapeutics, Inc.
    • Trophogen, Inc.
    • Vascular Biogenics Ltd.
  • Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BP-100-1.02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVA-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVA-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel liposomal - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EDC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETD-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenvatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVX-ONCO-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • panobinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize VEGF for Thyroid and Multiple Other Cancers - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize ALK for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TR-1401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRX-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thyroid Cancer - Recent Pipeline Updates
  • Thyroid Cancer - Dormant Projects
  • Thyroid Cancer - Discontinued Products
  • Thyroid Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2014: Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility For New Cancer Treatment in Hatfield, UK
      • Oct 14, 2014: U.S. FDA Grants Eisai's Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer
      • Sep 17, 2014: Eisai to Present Clinical Data on Lenvatinib at 39th ESMO Congress
      • Sep 06, 2014: Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses
      • Aug 18, 2014: Eisai submits Marketing Approval Application for Anti cancer Agent Lenvatinib Simultaneously in Europe And U.S.
      • Jul 31, 2014: Ema Accepts Eisai's Request For Accelerated Assessment Of Anticancer Agent Lenvatinib
      • Jun 26, 2014: Eisai Submits First Marketing Authorization Application for Anticancer agent Lenvatinib in Japan
      • May 31, 2014: Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
      • May 15, 2014: Eisai to Present Abstracts On Lenvatinib At 50th ASCO Annual Meeting
      • Feb 03, 2014: Phase III Trial Shows Lenvatinib Meets Primary Endpoint Of Progression Free Survival Benefit in Treatment Of Radioiodine-refractory Differentiated Thyroid Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thyroid Cancer, H2 2014
  • Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014
  • Thyroid Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014
  • Thyroid Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014
  • Thyroid Cancer - Pipeline by Biovista Inc., H2 2014
  • Thyroid Cancer - Pipeline by centrose llc, H2 2014
  • Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2014
  • Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2014
  • Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014
  • Thyroid Cancer - Pipeline by Novartis AG, H2 2014
  • Thyroid Cancer - Pipeline by Translational Therapeutics, Inc., H2 2014
  • Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2014
  • Thyroid Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014
  • Thyroid Cancer - Dormant Projects, H2 2014
  • Thyroid Cancer - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Thyroid Cancer, H2 2014
  • Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top